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 Introductions: Colorectal carcinoma is the third most common cancer 
worldwide. The incidence is increasing in developing countries including 
Nepal. The aim of this study is to find out the clinicopathological pattern 
of colorectal carcinoma locally. 
 
Methods: Data were recorded retrospectively by reviewing the charts of 
the patients who were diagnosed and treated for in patients having 
colorectal cancer managed during three years period of 2016-9 at Patan 
Hospital, the university teaching hospital of Patan Academy of health 
sciences, Nepal. Clinicopathological profile, age, gender, surgery, 
histopathological findings were descriptively analised. 
 
Results:  There were 36 colorectal cancer patients, male 20 (56%) and 
females 16 (44%), mean age 56.9 years (range 24 to 89). Curative surgery 
was possible in 17 (47.2%) and adenocarcinoma of moderate 
differentiation was found in 25 (70%) of the resected specimen. 
 
Conclusions: Colorectal carcinoma was found in old age, slightly more in 
male than female, adenocarcinoma being most common histology type.   
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Colorectal carcinoma (CRC) is more common in 
elderly with a median age of 68 years (range, 
25-93 years).1 Around 15 to 30% of CRCs 
present as a surgical emergency, as 
obstruction (78%), perforation (10%), or 
bleeding (4%).2,3   
  
In WHO South east Asia region the reported 
proportion of colorectal cancer in men is 
56.7%and in women 43.2% among 120225 
case of colorectal cancer. Similarly, in India 
which is similar to our geographical region the 
proportion is 57.4% in male and 42.6% in 
female among 64332 detected colorectal 
cases.4 The overall incidence is increasing in 
developing countries including Nepal.5 
Epidemiological change of colorectal cancer 
has been observed in the past with increased 
incidence in young age.6  
 
This is a followup study of similar study done at 
our institute.7 The aim of this study was to 
analyse the clinicopathological pattern of CRC 
in local scenario, to find out changing trends in 
the CRC especially pathological aspects and 








An institution based retrospective study was 
performed on all the patients managed at the 
department of surgery, Patan hospital, Patan 
academy of health sciences Nepal during three 
years period from Aug 2016 to Sept 2019. 
Patients preoperative diagnosis of CRC by 
Colonoscopy/Contrast enhanced computed 
tomography (CECT)/ Magnetic resonance 
imaging (MRI) or pre-operative 
Histopathological examination (HPE) and Fine 
needle aspiration cytology (FNAC) (in 
advanced disease) were included, as well as 
who were diagnosed intraoperatively. 
Incomplete records or patients charts which 
were not available for analysis were excluded. 
Medical records were retrieved by searching a 
hospital computer database using 
International Classification of Diseases, 10th 
revision (ICD 10 code) “C20” for rectal and 
“C18” for colon carcinoma. Institutional review 
committee approval was obtained. Patients 
files were reviewed for demographics (age and 
sex), duration of symptoms (days), presenting 
symptoms (pain abdomen, PR bleeding, 
abdominal mass, rectal mass and pallor, 
associated symptoms (weight loss, pre-
treatment diagnostic findings (Ultrasongram 
(USG), CT/MRI, colonoscopy biopsy, level of 
carcinoembryonic antigen( CEA), involved part 
of colon, type of surgery, surgical clearance in 
curative, histological tumor type, post-
operative adjuvant treatment, palliative 
treatment, recurrence and followup were 
recorded. Last date of followup was recorded 
and duration was calculated from the date of 
initial diagnosis and start of treatment or 
surgery. Recurrence of the operated patient 
was noted if there was an obvious diagnosis of 
recurrence at the time of last followup. Data 
were descriptively (mean and percentage) 







Record of 42 patients were found by ICD 10 
search “C20 and “C18” but only 36 patients’ 
charts could be retrieved for final analysis. Out 
of 36 CRC, male was 20 (56%) and female 16 
(44%), mean age 56.9±16.9 years (range 24-
89). Six (16.7%) patient were below 40 years of 
age, thirteen (36.1%) were between 40-60 
years and 17 (47.2%) were above 61 years of 
age. Altogether, majority (83.3%) were above 
40 years.  
 
 
Abdominal pain was present in 31 (86%), 
followed by per rectal (PR) bleeding in 20 
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Table 1. Presenting signs and symptoms of CRC (N=36) 
 
 
Presenting signs symptoms N  % 
Pain abdomen 31 86% 
PR bleeding 20 55% 
Palpable abdominal mass / rectal mass 7 19% 
Pallor 8 22% 
 
Table 2. Location of CRC (N=36) 
 
 
Involved segment N % 
Rectum including rectosigmoid 23 63.8% 
Ascending colon 7 19% 
Descending colon 4 4% 
Ca caecum 1 2% 
Transverse colon 1 2% 
 
Table 3. Types of surgery performed for CRC (N=36) 
 
 
Type of surgery N % 
Right hemicolectomy  4 20% 
Left hemicolectomy 4 20% 
Anterior resection (AR) 4 20% 
Low anterior resection (LAR) 3 15% 
Ultra LAR 1 5% 
Sigmoidectomy  1 5% 
Palliative surgery Diverting colostomy 1 5% 
Transvers colon mass excision with en block partial gastrectomy 1 5% 
Non curative right hemicolectomy 1 5% 
 
Table 4. Histology type of CRC after surgery (N=20) 
 
 
Histology type N % 
Moderately differentiated 14 70% 
Mucinous adenocarcinoma 4 20% 
Poorly differentiated 1 5% 
Complete response after neoadjuvant treatment (no tumour cells) 1 5% 
 
Table 5. Tumor (T stage) and lymph node (N) status in curative surgery of CRC (N=17) 
 
 
Tumor Stage  N % 
T stage 
T0      1* 5.8% 
T1 2 11.7% 
T2 4 23.5% 
T3 6 35.3% 
T4  4 23.5% 
N stage 
N0 8 47% 
N1 (1-3 nodes) 5 29% 
N2 (4-6 nodes) 4 23.5% 
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Rectum and rectosigmoid involvement was 
found in 23 (63.8%). Overall, left colon was 
affected in 27 (75%) and right in 9 (25%). (Table 
2) 
 
All patients had preoperative colonoscopy or 
sigmoidoscopy and biopsy, showing 
malignancy in 31 (86.1%) and 5 (13.9%) had 
acute on chronic colitis. 
 
All the patients (36) had undergone a CECT 
examination with diagnosis of CRC. Among 36 
CECT, 20 were done prior to surgery, and 16 
before neoadjuvant or palliation. In 28 (77.8%) 
patients CEA was done, of which 18 (64.2%) it 
was ≥4 ng/ml, in 10 (35.7%) <4 ng/ml. 
 
Surgery was done in 20 (55.5%), of which 17 
(85% of 20) were curative resection, Table 3. 
   
Out of 36 patients, 20 patients underwent 
surgery in our hospital, 17 had curative 
resections and 3 had palliative care. 
 
The HPE in 20 surgery showed moderately 
differentiated adenocarcinoma in 14 (70%). 
One patient who had neoadjuvant treatment, 
HPE showed no residual microscopic tumor 
cells, Table 4. Lymphovascular invasion (LVI) 
was seen in 5 (25%), perineural invasion (PNI) 
in 4 (20%) and 2 (10 %) had both LVI and PNI.  
Surgical margin was free in 19 patients (R0) and 
one patient with en bloc partial gastrectomy 
showed positive resection margin. In curative 
resection, the lymph node yield ranged from 1 
to 37, mean 12.5±9.1. Among them mean 
lymph node positivity was 1.87±2 ranging from 
0-5.  Two patients had T1 and eight N0, Table 
5. Out of twenty operated patients, six had 
adjuvant chemotherapy.   
 
Followup was available in 30 (83.3%) patients, 
average 36.2 weeks (range 1-156). Short 
followup was noted in the patients with the 
advanced disease 16 (44.4%) and 9 (25%) had 
palliative care and 7 (19.4%) referred to other 
center for chemotherapy and radiotherapy. 
Among 20 operated patients one death 





In our study we found that 6 (16.7%) patients 
were below 40 years of age.  However, earlier 
study7 at our center showed 29% of patients 
were below 40 years of age. This may be due 
to smaller sample size of 36 and lesser duration 
of 3 years in present study, than earlier study 
at our center with sample size of 73 during 8 
years. And so, this is not necessarily the real 
decline of CRC in younger age of <40 years 
locally. Literatures show CRC is rare before the 
age of 40 years, and the incidence begin to 
increase significantly between the age of 40 
and 50 years and age-specific incidence rates 
increasing in succeeding decades thereafter.8 It 
has been seen that 90% of new cases are 
diagnosed in patients over 50 years of age, but 
now incidence in the younger population is 
increasing and they present in a more 
advanced stage.9  Worldwide, CRC is the third 
most common cancer and the third leading 
cause of cancer-related death in both males 
and females.10,11 Globally, the highest 
incidence of CRC rates are in North America, 
Australia, and Europe, and the lowest rates in 
Africa and Asia.10,11   So far there is lack true 
incidence of CRC in Nepal. Data from our 
center, 73 during 2004-12 earlier study,7 plus 
36 during 2016-2019 in present study, total 99 
in 11 years, suggest that it is not uncommon 
and number of CRC is in the rise. 
 
Study with larger sample size of 22432 cases of 
CRC between 2000 and 2011 from China found 
that the age-specific rates were relatively low 
in populations younger than 40 years for both 
males and females and a dramatic increasing 
incidence after 40 years of age, which peaked 
at 80 years, and declined after 85 years of 
age.12 A multicenter study involving 1525 CRC 
cases between 2005 and 2014 as part of 
genetic and epidemiological studies from 
Colombia reports average age at diagnosis was 
57.4 years, with 26.5% of cases having early-
onset diagnosed by the age of 50 years).13 
 
We found male (20) and female (16) ratio is 
near equal (1:1.2). A study done in US in 
373,956 patients over 40 years of age 
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and 2006 who resided in one of the nine 
Surveillance, Epidemiology and End Results 
(SEER) regions of also had equal numbers of 
men (187973) and women (185983), however, 
men had significantly higher age-adjusted CRC 
incidence rates across all categories of age, 
race, tumor sub-site, stage, and SEER region. 
Gender differences in CRC incidence rates for 
the 40–49 and 50–59 age categories were 
small and increased only slightly over time.14 
 
Our analysis showed that 31 (86%) patients 
came with abdominal pain and 20 (55%) with 
notable PR bleeding, Table 1. A retrospective 
study involving 236 patients reports that the 
most common symptom is abdominal pain 121 
(51.3%) followed by weight loss 77 (32.6%) and 
change in bowel habit 34 (14.5%). The noticed 
bleeding, change in bowel habit and weight 
loss occurred more in left than right colon.15 
 
However, in our analysis even though 55% of 
patients had PR bleeding, less than 19% had a 
mass per rectum in DRE. Our policy is to do at 
least sigmoidoscopy in all the patients with PR 
bleeding after exclusion of fissures even if DRE 
negative and proctoscopy revealing 
hemorrhoids. A review article (on the basis of 
other non- English article) states- the 
importance of DRE (digital rectal examination) 
along with the case history recognized 70% of 
rectal cancers and 30% of CRCs and the 
accuracy of the examination increases with the 
experience of the doctor.16   
 
All our patient during study period had 
undergone CECT prior to treatment. Based on 
CECT findings, 20 (55.5%) underwent surgery 
of out 36. Out of 20 surgeries, 17 (85%) had 
curative resection and three palliations for 
obstructive symptoms. In difference to earlier 
study when there was lack of CT facility at our 
center. 
 
All our 36 CRC had colonoscopy or 
sigmoidoscopic examination. This is important 
both for detection and confirmation of CRC. It 
is recommended internationally and nationally 
by gastroenterology and cancer societies as an 
initial screening modality.17 Identification of 
CRC on screening colonoscopy has advantage 
of detection at lower-stage and better 
outcomes.18 However, there has been an 
increasing concern about the effectiveness of 
endoscopy in detecting adenomas and CRC in 
the right colon.19  
 
We found that out 30 CRC patient tested for 
CEA, 18 had more than 4 ng/ml. Our practice is 
to do CEA in all suspected CRCs, but six reports 
were missing in present study. High 
preoperative levels of CEA correlate with 
adverse prognosis. Serial measurements can 
detect recurrence with a sensitivity of 80%, a 
specificity of 70%. It also provides a lead time 
of approximately 5 months and currently, the 
most useful application of CEA is in the 
detection of liver metastasis from colorectal 
cancers.20  
 
We use CEA value of >4 ng/L as cut off for CRC. 
Systematic Reviews of 52 studies reports 
overall sensitivity of 41% to 97% and specificity 
from 52% to 100% in detection of recurrence 
of CRC.21 The review further mentions that 
based results of seven studies with a threshold 
of 2.5 ng/L, had sensitivity of 82% and 
specificity 80%. Other 23 studies with a 
threshold of 5 ng/L, sensitivity was71% and 
specificity 88%. Yet another seven studies with 
10 ng/L, had sensitivity of 68% and specificity 
97%. Thus, CEA is insufficiently sensitive to be 
used alone. Therefore, recommendation is to 
monitor recurrence with more than one 
diagnostic modality but applying the highest 
CEA cut-off value of 10 ng/L.21 
 
Our study shows more left sided malignancy 
i.e. 27 (75%) including descending, sigmoid 
colon and rectum. In a review article, the rectal 
cancers, once accounting for more than 50% of 
CRCs in the West, have now decreased to less 
than colon cancers. This review emphasizing 
the three entity of CRC, namely 1) right sided 
proximal to the splenic flexure - Caecum, 
Ascending colon, Transverse colon; 2) left 
sided distally to this site descending colon and 
sigmoid colon; and 3) rectum.22  
 
The CRC registry of SEER including 220000 
cases reported proximal colon carcinoma rates 





Sanjaya Paudyal: Clinicopathological profile of colorectal cancer 
Journal of Patan Academy of Health Sciences. 2019Dec;6(2):31-38. 
 
carcinoma, throughout the study period in the 
US.23 However, according our study left sided 
27 (75%), Table 2. 
 
In present study, among 20 operated patients 
of CRC, 70% were moderately differentiated 
adenocarcinoma, Table 4. Literature shows, 
more than 90% of CRC are adenocarcinomas 
and most colorectal adenocarcinomas (70%) 
are moderately differentiated, whereas well 
and poorly differentiated carcinomas account 
for 10% and 20%, respectively.24 Out of 20 
patients, LVI was seen in 5 (25%), PNI in 4 (20%) 
and only two had both (PNI+LVI). The LVI and 
PNI represents advanced stage of CRC and risk 
of recurrence. In a study of 2649 patients 
regarding LVI and PNI in rectal cancers, 
concluded that Stage II rectal cancer patients 
with LVI and PNI had increased risk of 
recurrence.25 Another study reported that LVI 
was positive in 26.3% out of 139026 patients, 
PNI was positive in 11.1% out of 142034 
patients. The PNI is an independent poor 
prognostic marker for survival in CRC.26 We did 
not analyze LVI and PNI positivity with 
outcome in our study because of retrospective 
nature and short followup. 
 
In a phase-3 non inferiority trial of 6088 
patients (receiving CAPEOX vs FOLFOX and 3 vs 
6 months) concluded that 3 months of 
oxaliplatin-containing adjuvant chemotherapy 
was non-inferior to 6 months of the same 
therapy for patients with high-risk stage II and 
stage III colorectal cancer and was associated 
with reduced toxicity and improved quality of 
life.27 In our study, 12 patients were referred 
for adjuvant treatment at other center and 
detail were not available.  
 
Out of 36 patients, we could trace 30 till their 
last followup visit, with average of 36 weeks 
and maximum 156 weeks. Our institute lacked 
both medical and radiation oncology services 
earlier during the study period. Now we have 
started medical oncology service since last six 
months. Majority of patients who were sent 
for neoadjuvant treatment were lost to follow, 
12 (of 17 curative resections i.e. 70.5%) who 
were referred out for adjuvant treatment did 
not come for regular followup. Also there was 
no mechanisms to trace them. 
 
Comparing earlier study7 from our center 
reported 52 (71.2%) CRC in >40 years and 21 
(28.8%) in <40, similar to present study with 
majority 30 (83.3%) >40 years and 6 (16.7) and 
no difference in sex in both the studies. 
Moderately differentiated adenocarcinoma is 
the most common (70%) histologic type found 
in current study as compared to earlier study 
(22.2%). In current study out 20 surgeries, 17 
(85%) had curative resection, possibly due to 
better CECT staging and segregation for 
adjuvant or palliative treatment avoiding non-
curative resections, this data was lacking in 
earlier study.  
 
Even though this is a low volume center with 
small sample size the findings are comparable, 
and a multicenter pooled data will provide 
better understanding of the CRC in Nepal. 
Limitations of present study is inherent of 






Our findings show CRC is still the disease of 
older age (>40 years) seen in 83.3% with a 
nearly equal incidence between male and 
female, though younger age (<40) is not spared 
and seen in 16.7%. Early detection confirms a 
high chance of curative surgery.  Moderately 
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